Regional body composition and functional impairment in patients with myotonic dystrophy

Muscle and Nerve

Volumn 44, Issue 4, 2011, Pages 503-508

  Pruna, Lelia ^a   Chatelin, Jerome ^a   Pascal Vigneron, Veronique ^a   Kaminsky, Pierre ^a  

^a CHU NANCY BRABOIS   (France)

Author keywords

Dual energy X ray absorptiometry; Fat tissue; Lean tissue; Muscular function; Myotonic dystrophy

Indexed keywords

ADULT; AGED; ANTHROPOMETRY; ARTICLE; BODY COMPOSITION; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FUNCTIONAL DISEASE; HUMAN; HYPERTRIGLYCERIDEMIA; MALE; MOTOR PERFORMANCE; MYOTONIC DYSTROPHY; PRIORITY JOURNAL; TOTAL LUNG CAPACITY; VITAL CAPACITY;

ABSORPTIOMETRY, PHOTON; ADIPOSE TISSUE; ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTHROPOMETRY; BODY COMPOSITION; BODY MASS INDEX; FEMALE; HUMANS; LUNG; LUNG VOLUME MEASUREMENTS; MALE; MIDDLE AGED; MOTOR ACTIVITY; MUSCLE, SKELETAL; MYOTONIC DYSTROPHY; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 80052877093     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.22099     Document Type: Article

References (24)

1. Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 30 end of a transcript encoding a protein kinase family member. Cell 1992;69:385.
2. Harper PS, Monckton DG. Myotonic dystrophy. In: Engel AG, Franzini-Amstrong C, editors. Myology: basic and clinical, 3rd ed. New York: McGraw-Hill; 2005. p 1039-1076.
3. Aitkens S, Kilmer DD, Wright NC, McCrory MA. Metabolic syndrome in neuromuscular disease. Arch Phys Med Rehabil 2005;86: 1030-1036.
4. Johansson A, Andrew R, Forsberg H, Cederquist K, Walker BR, Olsson T. Glucocorticoid metabolism and adrenocortical reactivity to ACTH in myotonic dystrophy. J Clin Endocrinol Metab 2001;86: 4276-4283.
5. Paterson JM, Morton NM, Fievet C, Kenyon CJ, Holmes MC, Staels B, et al. Metabolic syndrome without obesity: hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci USA 2004;10:7088-7093.
6. Perseghin G, Caumo A, Arcelloni C, Benedini S, Lanzi R, Pagliato E, et al. Contribution of abnormal insulin secretion and insulin resistance to the pathogenesis of type 2 diabetes in myotonic dystrophy. Diabetes Care 2003;26:2112-2118.
7. Kanda F, Fujii Y, Takahashi K, Fujita T. Dual-energy X-ray absorptiometry in neuromuscular diseases. Muscle Nerve 1994;17:431-435.
8. Skalsky AJ, Abresch RT, Han JJ, Shin CS, McDonald CM. The relationship between regional body composition and quantitative strength in facioscapulohumeral muscular dystrophy (FSHD). Neuromuscul Disord 2008;18:873-880.
9. Nau KL, Dick AR, Peters K, Schloerb PR. Relative validity of clinical techniques for measuring the body composition of persons with amyotrophic lateral sclerosis. J Neurol Sci 1997;152(suppl 1): S36-S42.
10. Palmieri GM, Bertorini TE, Griffin JW, Igarashi M, Karas JG. Assessment of whole body composition with dual energy x-ray absorptiometry in Duchenne muscular dystrophy: correlation of lean body mass with muscle function. Muscle Nerve 1996;19:777-789.
11. Mathieu J, Boivin H, Meunier D, Gaudreault M, Begin P. Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy. Neurology 2001;56:336-340.
12. Berard C, Payan C, Hodgkinson I, Fermanian J, Group MFMCS. A motor function measure for neuromuscular diseases. Construction and validation study. Neuromuscul Disord 2005;15:463-470.
13. Shelbourne P, Davies J, Buxton J, Anvret M, Blennow E, Bonduelle M, et al. Direct diagnosis of myotonic dystrophy with a disease-specific DNA marker. N Engl J Med 1993;328:471-475.
14. Leroy-Willig A, Willig TN, Henry-Feugeas MC, Frouin V, Marinier E, Boulier A, et al. Body composition determined with MR in patients with Duchenne muscular dystrophy, spinal muscular atrophy, and normal subjects. Magn Reson Imaging 1997;15:737-744.
15. Rio A, Cawadias E. Nutritional advice and treatment by dietitians to patients with amyotrophic lateral sclerosis/motor neurone disease: a survey of current practice in England, Wales, Northern Ireland and Canada. J Hum Nutr Diet 2007;20:3-13.
16. Skalsky AJ, Han JJ, Abresch RT, Shin CS, McDonald CM. Assessment of regional body composition with dual-energy X-ray absorptiometry in Duchenne muscular dystrophy: correlation of regional lean mass and quantitative strength. Muscle Nerve 2009;39:647-651.
17. Sproule DM, Montes J, Montgomery M, Battista V, Koenigsberger D, Shen W, et al. Increased fat mass and high incidence of overweight despite low body mass index in patients with spinal muscular atrophy. Neuromuscul Disord 2009;19:391-396.
18. Zanardi MC, Tagliabue A, Orcesi S, Berardinelli A, Uggetti C, Pichiecchio A. Body composition and energy expenditure in Duchenne muscular dystrophy. Eur J Clin Nutr 2003;57:273-278.
19. Wang W, Wang Z, Faith MS, Kotler DP, Shih R, Heymsfield SB. Regional skeletal muscle measurement: evaluation of new dual energy X-ray absorptiometry model. J Appl Physiol 1999;87:1163-1171.
20. Hansen RD, Raja C, Aslani A, Smith RC, Allen BJ. Determination of skeletal muscle and fat-free mass by nuclear and dual-energy X-ray absorptiometry methods in men and women aged 51-84 y. Am J Clin Nutr 1999;70:228-33.
21. Matsumura T, Iwahashi H, Funahashi T, Takahashi MP, Saito T, Yasui K, et al. A cross-sectional study for glucose intolerance of myotonic dystrophy. J Neurol Sci 2009;276:60-65.
22. Day JW, Ranum LP. RNA pathogenesis of the myotonic dystrophies. Neuromuscul Disord 2005;15:5-16.
23. Rakocevic Stojanovic V, Peric S, Lavrnic D, Popovic S, Ille T, Stevic Z, et al. Leptin and the metabolic syndrome in patients with myotonic dystrophy type 1. Acta Neurol Scand 2010;121:94-98.
24. Shieh K, Gilchrist JM, Promrat K. Frequency and predictors of nonalcoholic fatty liver disease in myotonic dystrophy. Muscle Nerve 2010;41:197-201.